葵花药业(002737.SZ)：复方聚乙二醇(3350)电解质散获得药品注册证书

Core Viewpoint - The company, Kewang Pharmaceutical, has received approval from the National Medical Products Administration for its drug, Compound Polyethylene Glycol (3350) Electrolyte Powder, which is aimed at treating chronic constipation in children aged 1 to 11 and fecal impaction in children aged 5 to 11 [1] Group 1 - The drug is indicated for the treatment of chronic constipation in children aged 1 to 11 years [1] - The drug is also indicated for treating fecal impaction, specifically in children aged 5 to 11 years, which involves stubborn constipation accompanied by rectal and/or colonic fecal mass accumulation [1]